#1 Clinical Trials Search in Europe

Basimglurant

Basimglurant, also known as NOE-101, is an experimental drug being studied in clinical trials for various neurological conditions. This article explores the use of Basimglurant in treating trigeminal neuralgia, major depressive disorder, and tuberous sclerosis complex. We’ll discuss the drug’s mechanism of action, its potential benefits, and the ongoing research to determine its safety and effectiveness.

Table of Contents

What is Basimglurant?

Basimglurant, also known as NOE-101, is a new drug being studied for its potential to treat various medical conditions[1]. It is currently undergoing clinical trials to evaluate its effectiveness and safety in treating several disorders that affect the nervous system.

How Does Basimglurant Work?

Basimglurant works by inhibiting a specific protein in the body called metabotropic glutamate receptor 5 (mGluR5)[1]. This protein plays a crucial role in various processes in both the central nervous system (brain and spinal cord) and the peripheral nervous system (nerves outside the brain and spinal cord). By blocking this protein, Basimglurant may help reduce pain and control other symptoms associated with certain neurological conditions.

Conditions Treated with Basimglurant

Research is currently exploring the use of Basimglurant in treating several conditions:

  • Trigeminal Neuralgia (TN): This is a chronic pain condition affecting the trigeminal nerve in the face. It’s known for causing extreme, sudden burning or shock-like pain[1].
  • Major Depressive Disorder (MDD): A mental health condition characterized by persistent feelings of sadness and loss of interest in daily activities[2].
  • Tuberous Sclerosis Complex (TSC): A rare genetic disorder that causes non-cancerous tumors to grow in many parts of the body. In TSC, Basimglurant is being studied for its potential to control seizures, which are a common symptom of this condition[3].

Clinical Trials and Research

Several clinical trials are currently underway to evaluate the effectiveness and safety of Basimglurant:

  • Trigeminal Neuralgia Study: This trial aims to determine if Basimglurant can decrease both the duration and intensity of facial pain associated with TN. Researchers are using patient pain diaries and a scale called the Patient-reported Global Impression of Change (PGI-C) to measure the drug’s effectiveness[1].
  • Major Depressive Disorder Study: This trial is investigating the safety, tolerability, and how the body processes Basimglurant in healthy individuals and patients with MDD who are already taking antidepressants[2].
  • Tuberous Sclerosis Complex Study: This research is focused on finding the optimal dose of Basimglurant that can reduce the duration, frequency, and intensity of seizures in children, adolescents, and young adults with TSC[3].

Dosage and Administration

The dosage of Basimglurant varies depending on the condition being treated and the specific clinical trial:

  • For Trigeminal Neuralgia, doses range from 1.5 mg to 3.5 mg taken once daily[1].
  • In the Major Depressive Disorder study, doses start at 1.5 mg and can be increased up to 4.0 mg, with dose increases occurring no more frequently than every 4 days[2].
  • For the Tuberous Sclerosis Complex study, the exact dosage is not specified, as researchers are still determining the optimal dose for this condition[3].

In all cases, Basimglurant is taken orally (by mouth) once daily.

Safety and Side Effects

While Basimglurant is still being studied, initial research suggests it has a favorable safety profile in adults, children, and adolescents[1]. However, as with any medication, it may cause side effects. The ongoing clinical trials are closely monitoring for any adverse events.

Some of the safety measures being evaluated in the trials include:

  • Incidence and severity of adverse events
  • Changes in laboratory test results
  • Effects on vital signs and cardiovascular events
  • Impact on sleep habits
  • Potential for suicidal thoughts or behaviors

It’s important to note that Basimglurant is still an investigational drug, which means it has not yet been approved for general use by regulatory agencies like the FDA. More research is needed to fully understand its effectiveness and safety profile.

Aspect Details
Drug Name Basimglurant (NOE-101)
Mechanism of Action Inhibitor of metabotropic glutamate receptor 5 (mGluR5)
Conditions Studied Trigeminal Neuralgia, Major Depressive Disorder, Tuberous Sclerosis Complex
Administration Oral capsules, once daily
Dosage Range 1.5 mg to 4.0 mg (varies by trial)
Primary Outcomes Pain reduction, seizure frequency, safety and tolerability
Trial Designs Randomized, double-blind, placebo-controlled with open-label extensions
Safety Monitoring Adverse events, vital signs, laboratory tests, ECG, suicidality assessment
Patient Populations Adults, children, adolescents, and young adults (depending on the trial)
Current Status Phase II/III trials ongoing

FAQ

  • What is Basimglurant and how does it work? Basimglurant (NOE-101) is a potent inhibitor of metabotropic glutamate receptor 5 (mGluR5). This receptor controls various processes in the brain, spinal cord, and nervous system. By inhibiting mGluR5, Basimglurant may help reduce pain, seizures, and other neurological symptoms in different conditions.
  • Which conditions are being studied with Basimglurant? Clinical trials are investigating Basimglurant for trigeminal neuralgia (a facial pain condition), major depressive disorder, and tuberous sclerosis complex (a genetic disorder causing seizures and other symptoms).
  • How is Basimglurant administered in clinical trials? Basimglurant is given as oral capsules, typically once daily. The dosage may vary depending on the specific trial and condition being studied. Some trials use a titration approach, gradually increasing the dose over time.
  • What are the primary outcomes being measured in these trials? The trials are measuring various outcomes, including changes in pain levels for trigeminal neuralgia, reduction in seizure frequency for tuberous sclerosis complex, and safety and tolerability across all conditions. They also assess the drug's effects on quality of life and overall symptom improvement.
  • Are there any known side effects of Basimglurant? While the full safety profile is still being established, the trials are closely monitoring for adverse events. Some studies are specifically looking at effects on sleep, suicidal thoughts, and heart rhythm (QT interval). Previous trials have shown a favorable safety profile in adults, children, and adolescents.

Ongoing Clinical Trials on Basimglurant

  • Study on Basimglurant for Children, Adolescents, and Young Adults with Tuberous Sclerosis Complex-Related Seizures

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Italy Poland Spain

  • Study on Basimglurant for Treating Pain in Patients with Trigeminal Neuralgia

    Not recruiting

    4 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany Italy Poland Spain

Glossary

  • Basimglurant (NOE-101): An experimental drug that inhibits metabotropic glutamate receptor 5 (mGluR5), being studied for various neurological conditions.
  • Trigeminal Neuralgia: A chronic pain condition affecting the trigeminal nerve in the face, often described as one of the most painful conditions known.
  • Major Depressive Disorder (MDD): A mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities.
  • Tuberous Sclerosis Complex (TSC): A genetic disorder that causes non-cancerous tumors to grow in various organs, often leading to seizures and other neurological symptoms.
  • Metabotropic Glutamate Receptor 5 (mGluR5): A protein in the nervous system that plays a role in various neurological processes and is the target of Basimglurant.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • QT Interval: A measurement on an electrocardiogram that represents the time for electrical activity in the heart's ventricles.
  • Titration: The process of gradually adjusting the dose of a medication to find the optimal balance between effectiveness and side effects.
  • Open-Label Extension (OLE): A phase of a clinical trial where all participants receive the active drug, often following a placebo-controlled phase.
  • Patient Global Impression of Change (PGI-C): A scale used to measure a patient's perception of improvement or worsening of their condition during a clinical trial.

References